X4 Pharmaceuticals, Inc.
XFOR · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $35.1M | $2.56M | +1,271% |
| Operating income | −$86.9M | −$36.4M | −139% |
| Net income | −$79.2M | −$37.5M | −111% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 4, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $2.90M | $1.80M | +61.1% |
| Operating income | −$20.0M | −$27.5M | +27.3% |
| Net income | −$20.2M | −$29.8M | +32.2% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was X4 Pharmaceuticals's revenue in FY2025?
- $35.1M in FY2025 (Fiscal year ended Dec 31, 2025), +1,271% vs $2.56M a year earlier, per its 10-K filed Mar 2026.
- Was X4 Pharmaceuticals profitable in FY2025?
- No: net income was −$79.2M and operating income −$86.9M in FY2025.
- What was X4 Pharmaceuticals's revenue in Q3 2026?
- $2.90M (+61.1% vs a year earlier), per its Form 10-Q filed Nov 4, 2026.